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1. INTRODUCTION {#mgg3888-sec-0005}
===============

Cardiovascular diseases (CVDs) as the type of age‐related disease including coronary artery disease (CAD), stroke, hypertension, and cerebral infarction, which are one of the main causes of morbidity and mortality in the world (Chen et al., [2017](#mgg3888-bib-1003){ref-type="ref"}; Mozaffarian et al., [2016](#mgg3888-bib-0042){ref-type="ref"}; Song et al., [2017](#mgg3888-bib-0048){ref-type="ref"}; Sun et al., [2017](#mgg3888-bib-0052){ref-type="ref"}; Yu et al., [2017](#mgg3888-bib-0059){ref-type="ref"}; Yusuf, Reddy, Ôunpuu, & Anand, [2001](#mgg3888-bib-0060){ref-type="ref"}; Zhao et al., [2016](#mgg3888-bib-0062){ref-type="ref"}). The clinical risk factors about CVDs have been established for many years, including obesity, hypertension, diabetes, and an inactive lifestyle (Cooper et al., [2000](#mgg3888-bib-0007){ref-type="ref"}; Kaess et al., [2015](#mgg3888-bib-0023){ref-type="ref"}; Yusuf et al., [2001](#mgg3888-bib-0060){ref-type="ref"}). However, the pathological statistical concept suggested that the complex molecular basis of CDV was related to a wide range of biological pathways, involving lipid and glucose metabolism, vascular repair and angiogenesis (Gaziano et al., [2006](#mgg3888-bib-0017){ref-type="ref"}). Several studies have shown that the etiology and pathogenesis of CVDs were likely to comprise a multifactorial disorder resulting from environmental and genetic factors (Cooper, [1999](#mgg3888-bib-0006){ref-type="ref"}). Apart this, more and more researches identified that inflammatory molecules might play a central role in the pathogenesis of Cardiovascular diseases as well (Marousi, Ellul, et al., [2011](#mgg3888-bib-0039){ref-type="ref"}).

The occurrence and development of arterial thrombotic diseases are involved in the inflammation (Meuwissen et al., [2004](#mgg3888-bib-0041){ref-type="ref"}). Inflammatory cytokines are recognized as dysregulated in aging and age‐related disease (Liu, Wang, & Jiang, [2017](#mgg3888-bib-0035){ref-type="ref"}). Interleukin 10 (*IL‐10*, OMIM: 226,990), as a potent immunoregulatory cytokine, is a newly discovered cytokine in recent years, which is widely known for its anti‐inflammatory and B‐cell stimulating function (Franceschi & Campisi, [2014](#mgg3888-bib-0016){ref-type="ref"}; Rea et al., [2018](#mgg3888-bib-0046){ref-type="ref"}). According to the chromosomal location and functional relevance, *IL‐10* is a multifunctional cytokine that could not only inhibit the synthesis of proinflammatory cytokines but also downregulate antigen presentation and macrophage activation (Lee, Kim, & Song, [2014](#mgg3888-bib-0029){ref-type="ref"}). Scientific literature reported that *IL‐10* was related to the pathogenesis and development of coronary artery inflammation (Heeschen et al., [2003a](#mgg3888-bib-0019){ref-type="ref"}), and have been considered a candidate gene for kind of cardiovascular diseases (CVD) (Liu, Hui‐Min, Yang, & Geriatrics, [2017](#mgg3888-bib-0034){ref-type="ref"}), including vasculitis, cerebral infarction, atrial fibrillation, atherosclerotic, and stroke, but the results are still controversial. Therefore, this meta‐analysis was performed to obtain a more precise conclusion and to make a better understanding of *IL‐10* (−1082 G/A) single‐nucleotide polymorphism (SNP) with CVDs risk.

Currently, many epidemiological studies have focused on the relationship between *IL‐10* (−1082 G/A) SNP and CVDs risk, including CAD, stroke, hypertension, and cerebral infarction, but the results are still controversial (Afzal et al., [2012](#mgg3888-bib-0001){ref-type="ref"}; Ben‐Hadj‐Khalifa et al., [2010](#mgg3888-bib-0003){ref-type="ref"}; Karaca, Kayıkçıoğlu, Onay, Gündüz, & Ozkınay, [2011b](#mgg3888-bib-0025){ref-type="ref"}; Marousi, Ellul, et al., [2011](#mgg3888-bib-0039){ref-type="ref"}; Zhang, Pan, Ran, & Bing‐Xun, [2007](#mgg3888-bib-0061){ref-type="ref"}). Furthermore, a single study might be too underpowered to provide accurate conclusion because of relatively small sample size. In order to reach a reliable conclusion, we designed this meta‐analysis to assess the relationship of *IL‐10*(−1082 G/A) SNP with the risk of CVDs.

2. MATERIALS AND METHODS {#mgg3888-sec-0006}
========================

2.1. Inclusion and exclusion criteria {#mgg3888-sec-0007}
-------------------------------------

We executed an extensive search for databases including PubMed, Embase, and Web of Science to confirm relevant research to analyze the association between the *IL‐10* polymorphisms and CVDs risk. The last report was updated on April 17, 2017. When included in the analysis, qualified researches must meet the following criteria: (1) the association studies about the *IL‐10* polymorphism and susceptibility to related CVDs must follow case--control study strategies; (2) all patients meet the diagnostic criteria for CVDs in the candidate studies; (3) There is enough available data to calculate the odds ratio (OR) and 95% confidence interval (CI). The major exclusion criteria for studies were: (a) not a case--control study; (b) studies that have been republished; and (c) no feasibility data studies. This meta‐analysis was performed conforming to the Preferred Reporting Items for Systematic Reviews and Meta‐analyses (PRISMA) guidelines. Finally, data for meta‐analysis were available from 31 studies, including 10,502 cases and 7,865 controls 61 (Afzal et al., [2012](#mgg3888-bib-0001){ref-type="ref"}; Benhadjkhalifa et al., [2010](#mgg3888-bib-0002){ref-type="ref"}; Cruz et al., [2013](#mgg3888-bib-0009){ref-type="ref"}; Donger et al., [2001](#mgg3888-bib-0010){ref-type="ref"}; Elsaid, Abdelaziz, Elmougy, & Elwaseef, [2014](#mgg3888-bib-0012){ref-type="ref"}; Fragoso et al., [2011](#mgg3888-bib-0015){ref-type="ref"}; He et al., [2015](#mgg3888-bib-0018){ref-type="ref"}; Ianni et al., [2012](#mgg3888-bib-0020){ref-type="ref"}; Jiang, Lin, Zhang, Chen, & Liu, [2015](#mgg3888-bib-0021){ref-type="ref"}; Jin, Peihua, Jiemin, Yi, & Hailiang, [2011](#mgg3888-bib-0022){ref-type="ref"}; Karaca, Kayıkçıoğlu, Onay, Gündüz, & Ozkınay, [2011a](#mgg3888-bib-0024){ref-type="ref"}; Koch et al., [2001](#mgg3888-bib-0026){ref-type="ref"}; Kumar et al., [2016](#mgg3888-bib-0027){ref-type="ref"}; Li, Gao, He, & Zhang, [2016](#mgg3888-bib-0030){ref-type="ref"}; Lin, [2009](#mgg3888-bib-0031){ref-type="ref"}; Lio et al., [2004](#mgg3888-bib-0032){ref-type="ref"}; Liu, Li, Zhu, & He, [2017](#mgg3888-bib-0033){ref-type="ref"}; Lorenzová et al., [2007](#mgg3888-bib-0036){ref-type="ref"}; Marousi, Ellul, et al., [2011](#mgg3888-bib-0039){ref-type="ref"}; Munshi et al., [2010](#mgg3888-bib-0043){ref-type="ref"}; O\'Halloran, Stanton, O\'Brien, & Shields, [2006](#mgg3888-bib-0044){ref-type="ref"}; Ozkan, Sılan, Uludağ, Degirmenci, & Karaman, [2015](#mgg3888-bib-0045){ref-type="ref"}; Seifart et al., [2005](#mgg3888-bib-0047){ref-type="ref"}; Babu et al., [2012](#mgg3888-bib-0049){ref-type="ref"}; Sultana et al., [2011](#mgg3888-bib-0051){ref-type="ref"}; Tabrez et al., [2017](#mgg3888-bib-0053){ref-type="ref"}; Tuttolomondo et al., [2012a](#mgg3888-bib-0055){ref-type="ref"}; Yu et al., [2012](#mgg3888-bib-0058){ref-type="ref"}; Zhang et al., [2007](#mgg3888-bib-0061){ref-type="ref"}; Zheng et al., [2014](#mgg3888-bib-0063){ref-type="ref"}).

2.2. Data extraction {#mgg3888-sec-0008}
--------------------

Primary investigators used standardization requirements to extract qualified research from the database. They organized the data into tables and submitted them to coauthors for review to ensure that data are strict and reasonable. We collected the following information from the retrieved literature: first author\'s name, publication year, control source, country and ethnicity of population, the methods of genotype, the number of cases and controls, the distribution of genotype in cases and controls, and the *p* value for HWE (Hardy--Weinberg Equilibrium) in controls. Different ethnicity was categorized as Asians, Caucasians, and Mixed.

2.3. Statistical analyses {#mgg3888-sec-0009}
-------------------------

The *IL‐10* (−1082 G/A) polymorphisms and CVDs risk was assessed by OR and the corresponding 95% CI for each study. Different ORs (95% CI) were calculated using the following models: the allele model (G vs. A), the dominant model (GG + AG vs. AA), the recessive model (GG vs. AG + AA), the homozygote model (GG vs. AA), and the heterozygote model (GA vs. AA). Using the Cochran's *Q* statistic and *I* ^2^ test to evaluated the statistical heterogeneity between eligible studies, which was considered as significant when *p* ~Q~＜0.1 or *I* ^2^ \> 50%. A fixed‐effect model (the Mantel--Haenszel method) was adopted if *p* \> .1 and *I* ^2^ \< 50%, and a random‐effect model (DerSimonian--Laird method) was used if *p* \< .1 and *I* ^2^ \> 50%. Furthermore, we conducted subgroup analysis based on ethnicity (Asian, Caucasian, or Mixed) and disease subtype (CAD, stroke, and cerebral infarction) to explore the sources of heterogeneity. All statistical analyses were performed using software STATA 15.0 (StataCorp LP).

3. RESULTS {#mgg3888-sec-0010}
==========

3.1. Eligible studies {#mgg3888-sec-0011}
---------------------

As shown in Figure [1](#mgg3888-fig-0001){ref-type="fig"}, the process of literature retrieval and exclusion is listed. In general, the preliminary comprehensive search was identified 813 relevant articles. According to the inclusion and exclusion criteria, this meta‐analysis is involving 31 case--control studies with 18,367 total sample sizes (10,502 cases and 7,865 controls).

![Flow chart showing study selection procedure](MGG3-7-e888-g001){#mgg3888-fig-0001}

The characteristics of the studies are listed in Table [1](#mgg3888-tbl-0001){ref-type="table"}. *IL‐10* (−1082 G/A) genotype distributions in the controls from all studies has carried on HWE (Table [2](#mgg3888-tbl-0002){ref-type="table"}). The 31 studies identified in this meta‐analysis including 14 studies of Caucasians, 15 studies of Asians, and two studies from mixed population. Among these researches, patients were mostly recruited in referral centers with CAD, stroke, cerebral infarction and myocardial infarction, and the controls have not any obvious disease.

###### 

Characteristics of eligible studies included in the meta‐analysis

  First author (year)                                                   Disease                                             Control source   Country          Ethnicity   Matching   Genotyping
  --------------------------------------------------------------------- --------------------------------------------------- ---------------- ---------------- ----------- ---------- ----------------
  Koch et al. ([2001](#mgg3888-bib-0026){ref-type="ref"})               Coronary artery disease and myocardial infarction   HB               Germany          White       Age, sex   AS‐PCR
  Donger et al. ([2001](#mgg3888-bib-0010){ref-type="ref"})             Myocardial infarction                               NA               Mixed            White       Age, sex   PCR‐SSCP
  Lio et al. ([2004](#mgg3888-bib-0032){ref-type="ref"})                Cardiovascular diseases                             HB               North Italy      White       Age        PCR‐SSP
  Lio et al. ([2004](#mgg3888-bib-0032){ref-type="ref"})                Coronary heart disease                              HB               South Italy      White       Age        PCR‐SSP
  Seifart et al. ([2005](#mgg3888-bib-0047){ref-type="ref"})            Cardiovascular diseases                             PB               Germany          White       NA         PCR‐RFLP
  O'Halloran et al. ([2009](#mgg3888-bib-1000){ref-type="ref"})         Coronary artery disease                             NA               Ireland          White       NA         AS‐PCR
  Zhang et al. ([2007](#mgg3888-bib-0061){ref-type="ref"})              Cerebral infarction                                 PB               China            Asian       NA         PCR‐RFLP
  Lorenzová et al. ([2007](#mgg3888-bib-0036){ref-type="ref"})          Myocardial infarction                               PB               Czech Republic   White       Age        PCR‐RFLP
  Lin et al. ([2009](#mgg3888-bib-1010){ref-type="ref"})                Cerebral infarction                                 HB               China            Asian       Age, sex   ARMS‐PCR
  Ben‐Hadj‐Khalifa et al. ([2010](#mgg3888-bib-0003){ref-type="ref"})   Coronary artery disease                             NA               Tunisia          White       Age, sex   AS‐PCR
  Munshi et al. ([2010](#mgg3888-bib-0043){ref-type="ref"})             Ischemic stroke,                                    PB               India            Asian       Age, sex   ARMS‐PCR
  Karaca et al. ([2011b](#mgg3888-bib-0025){ref-type="ref"})            Coronary artery disease                             NA               Turkey           White       Age        PCR‐RFLP
  Marousi, Ellul, et al. ([2011](#mgg3888-bib-0039){ref-type="ref"})    Ischemic stroke                                     PB               Greece           White       Age, sex   RT‐PCR
  Sultana et al. ([2011](#mgg3888-bib-0051){ref-type="ref"})            Cerebral infarction                                 PB               India            Asian       Age        ARMS PCR
  Jin et al. ([2011](#mgg3888-bib-0022){ref-type="ref"})                Cerebral infarction                                 HB               China            Asian       Age        RFLP‐PCR
  Fragoso et al. ([2011](#mgg3888-bib-0015){ref-type="ref"})            Acute coronary syndrome                             HB               Mexico           Mixed       Age, sex   RT‐PCR
  Babu et al. ([2012](#mgg3888-bib-0049){ref-type="ref"})               Cardiovascular diseases                             NA               India            Asian       Age, sex   ARMS‐PCR
  Afzal et al. ([2012](#mgg3888-bib-0001){ref-type="ref"})              Coronary artery disease                             HB               Pakistan         Asian       Age        ARMS‐PCR
  Ianni et al. ([2012](#mgg3888-bib-0020){ref-type="ref"})              Myocardial infarction                               NA               South Italy      White       NA         TaqMan
  Tuttolomondo et al. ([2012a](#mgg3888-bib-0055){ref-type="ref"})      Ischemic stroke                                     HB               Italy            White       Age        ASO‐PCR
  Yu et al. ([2012](#mgg3888-bib-0058){ref-type="ref"})                 Ischemic heart disease                              PB               Korea            Asian       NA         Pyrosequencing
  Cruz et al. ([2013](#mgg3888-bib-0009){ref-type="ref"})               Myocardial ischemia                                 NA               Mexico           Mixed       NA         TaqMan
  Elsaid et al. ([2014](#mgg3888-bib-0012){ref-type="ref"})             Cardiovascular                                      NA               Egypt            White       NA         PCR
  Zheng et al. ([2014](#mgg3888-bib-0063){ref-type="ref"})              Atrial fibrillation                                 PB               China            Asian       NA         PCR‐RFLP
  He et al. ([2015](#mgg3888-bib-0018){ref-type="ref"})                 Ischemic stroke                                     PB               China            Asian       Age        PCR‐RFLP
  Jiang et al. ([2015](#mgg3888-bib-0021){ref-type="ref"})              Ischemic stroke                                     HB               China            Asian       Age, sex   PCR‐RFLP
  Ozkan et al. ([2015](#mgg3888-bib-0045){ref-type="ref"})              Ischemic stroke                                     HB               Italy            White       Age        RT‐PCR
  Kumar et al. ([2016](#mgg3888-bib-0027){ref-type="ref"})              Ischemic stroke                                     PB               India            Asian       Age        PCR‐RFLP
  Li et al. ([2016](#mgg3888-bib-0030){ref-type="ref"})                 Ischemic heart disease                              PB               China            Asian       Age, sex   PCR‐RFLP
  Liu, Hui‐Min, et al. ([2017](#mgg3888-bib-0034){ref-type="ref"})      Ischemic heart disease                              PB               China            Asian       Age, sex   PCR‐LDR
  Tabrez et al. ([2017](#mgg3888-bib-0053){ref-type="ref"})             Cardiovascular diseases                             HC               KAUH             Asian       NA         PCR
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###### 

Genotype distribution among studies included in the meta‐analysis

  First author (year)                                                           Sample size   Case   Control   HWE                     
  ----------------------------------------------------------------------------- ------------- ------ --------- ----- ----- ----- ----- -------
  Koch et al. ([2001](#mgg3888-bib-0026){ref-type="ref"})                       1,791/340     540    874       377   105   161   74    0.407
  Donger et al. ([2001](#mgg3888-bib-0010){ref-type="ref"})                     1,107/1,082   242    486       256   231   477   244   0.944
  Lio et al. ([2004](#mgg3888-bib-0032){ref-type="ref"})                        142/153       60     52        30    30    75    48    0.942
  Lio et al. ([2004](#mgg3888-bib-0032){ref-type="ref"})                        90/110        44     29        17    28    56    26    0.846
  Seifart et al. ([2005](#mgg3888-bib-0047){ref-type="ref"})                    104/243       19     59        25    86    115   42    0.739
  O\'Halloran et al. ([2006](#mgg3888-bib-0044){ref-type="ref"})                1,598/386     324    784       490   77    138   117   0.004
  Zhang et al. ([2007](#mgg3888-bib-0061){ref-type="ref"})                      204/131       202    2         0     120   14    0     0.523
  Lorenzová et al. ([2007](#mgg3888-bib-0036){ref-type="ref"})                  284/568       90     98        40    207   255   106   0.083
  Lin ([2009](#mgg3888-bib-0031){ref-type="ref"})                               181/90        153    28        0     83    32    0     0.083
  Ben‐Hadj‐Khalifa et al. ([2010](#mgg3888-bib-0003){ref-type="ref"})           291/291       76     108       101   52    100   76    0.088
  Munshi et al. ([2010](#mgg3888-bib-0043){ref-type="ref"})                     480/470       92     241       147   63    218   189   0.991
  Karaca et al. ([2011b](#mgg3888-bib-0025){ref-type="ref"})                    86/88         20     44        22    21    44    23    0.996
  Marousi, Antonacopoulou, et al. ([2011](#mgg3888-bib-0038){ref-type="ref"})   145/145       47     71        27    53    71    21    0.723
  Sultana et al. ([2011](#mgg3888-bib-0051){ref-type="ref"})                    238/226       154    44        40    163   47    16    0.000
  Jin et al. ([2011](#mgg3888-bib-0022){ref-type="ref"})                        189/92        161    27        1     78    12    2     0.087
  Fragoso et al. ([2011](#mgg3888-bib-0015){ref-type="ref"})                    389/302       211    142       36    164   113   25    0.38
  Babu et al. ([2012](#mgg3888-bib-0049){ref-type="ref"})                       651/432       318    260       73    170   188   74    0.079
  Afzal et al. ([2012](#mgg3888-bib-0001){ref-type="ref"})                      93/99         6      77        10    4     92    3     0.000
  Ianni et al. ([2012](#mgg3888-bib-0020){ref-type="ref"})                      267/321       68     141       56    78    88    73    0.000
  Tuttolomondo et al. ([2012a](#mgg3888-bib-0055){ref-type="ref"})              96/48         58     14        24    20    17    11    0.065
  Yu et al. ([2012](#mgg3888-bib-0058){ref-type="ref"})                         173/313       150    22        1     275   38    0     0.253
  Cruz et al. ([2013](#mgg3888-bib-0009){ref-type="ref"})                       149/248       55     83        11    125   106   17    0.387
  Elsaid et al. ([2014](#mgg3888-bib-0012){ref-type="ref"})                     108/143       2      49        22    8     85    5     0.000
  Zheng et al. ([2014](#mgg3888-bib-0063){ref-type="ref"})                      117/100       84     27        6     55    35    10    0.221
  He et al. ([2015](#mgg3888-bib-0018){ref-type="ref"})                         260/260       41     124       95    29    108   123   0.475
  Jiang et al. ([2015](#mgg3888-bib-0021){ref-type="ref"})                      181/115       153    28        0     83    32    0     0.083
  Ozkan et al. ([2015](#mgg3888-bib-0045){ref-type="ref"})                      42/48         11     26        5     19    18    11    0.113
  Kumar et al. ([2016](#mgg3888-bib-0027){ref-type="ref"})                      250/250       11     77        162   4     37    209   0.127
  Li et al. ([2016](#mgg3888-bib-0030){ref-type="ref"})                         335/335       54     151       130   34    143   158   0.844
  Liu, Hui‐Min, et al. ([2017](#mgg3888-bib-0034){ref-type="ref"})              386/386       313    68        5     308   75    3     0.498
  Karami, Zabihzadeh, Shams, and Saki Malehi (1002)                             75/50         1      66        8     40    1     9     0.000
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3.2. Meta‐analysis databases {#mgg3888-sec-0012}
----------------------------

As shown in Tables [3](#mgg3888-tbl-0003){ref-type="table"} and [4](#mgg3888-tbl-0004){ref-type="table"}, the results including the association of the *IL‐10* (−1082 G/A) polymorphism and CVDs risk, as well as homozygote test and heterogeneity test. The combined results showed that the variant genotypes were related to increase the CVDs risk in different genetic models (OR = 1.06, 95% CI = 1.03--1.10 for the homozygote comparison model GG vs. AA; OR = 0.88, 95% CI = 0.73--1.06 for the heterozygote comparison model AG vs. AA; OR = 1.10, 95% CI: 1.04--1.15 for the allele model A vs. G; OR = 0.87, 95% CI: 0.72--1.04 for the dominant model GG + AG vs. AA; and OR = 1.03, 95% CI: 1.02--1.05 for the recessive model GG vs. AG + AA). The forest plots for −1082 G/A in the allele model are shown in Figure [2](#mgg3888-fig-0002){ref-type="fig"}. In subgroup analyses by ethnicity, our results were similar to the Caucasian population.

###### 

Stratified analyses of the association between IL‐10‐1082A/G polymorphisms and cardiovascular disease risk

  Variables           Allele model        Dominant model   Recessive model                                                                   
  ------------------- ------------------- ---------------- ----------------- ------------------- ------- ------- ------------------- ------- -------
  Total               1.10 (1.04--1.15)   0.000            0.000             0.87 (0.72--1.04)   0.036   0.000   1.03 (1.02--1.05)   0.000   0.000
  Ethnicity                                                                                                                                  
  Asian               1.27 (1.17--1.38)   0.000            0.000             0.73 (0.54--0.99)   0.000   0.000   1.31 (0.95--1.81)   0.000   0.000
  Caucasian           1.03 (0.96--1.09)   0.446            0.000             0.95 (0.76--1.20)   0.754   0.000   1.03 (0.85--1.25)   0.629   0.930
  Mix                 0.87 (0.72--1.05)   0.154            0.133             1.29 (0.76--2.22)   0.118   0.036   0.90 (0.58--1.39)   0.000   0.000
  Source of control                                                                                                                          
  HB                  1.10 (0.99--1.22)   0.063            0.000             0.88 (0.76--1.02)   0.080   0.000   1.12 (0.92--1.36)   0.246   0.150
  PB                  1.18 (1.08--1.28)   0.000            0.000             0.87 (0.76--0.99)   0.032   0.000   1.30 (1.14--1.49)   0.000   0.000

*p* ~OR~: *p* value from the odd ratio and obtained from *Z* test; *p* ~Het~: *p* value from the heterogeneity and obtained from the chi‐square test.
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###### 

Heterogeneity and homogeneity analyses of the association between *IL‐10*‐1082A/G polymorphisms and cardiovascular disease risk

  Variables           Homozygote (GG vs. AA)   Heterogeneity (AG vs. AA)                                       
  ------------------- ------------------------ --------------------------- ------- ------------------- ------- -------
  Total               1.06 (1.03--1.10)        0.009                       0.000   0.88 (0.73--1.06)   0.205   0.000
  Ethnicity                                                                                                    
  Asian               0.81 (0.50--1.31)        0.000                       0.000   0.75 (0.56--1.00)   0.003   0.000
  Caucasian           0.95 (0.74--1.21)        0.464                       0.00    0.97 (0.74--1.26)   0.853   0.000
  Mix                 1.22 (0.77--1.92)        0.406                       0.588   1.29 (0.72--2.33)   0.138   0.028
  Source of control                                                                                            
  HB                  0.84 (0.68--1.05)        0.14                        0.000   0.90 (0.77--1.04)   0.165   0.000
  PB                  0.82 (0.69--0.99)        0.039                       0.000   0.87 (0.75--0.99)   0.047   0.005

*p* ~OR~: *p* value from the odd ratio and obtained from *Z* test; *p* ~Het~: *p* value from the heterogeneity and obtained from the chi‐square test.
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![Forest plots for the *IL‐10*‐1082A/G polymorphism and cardiovascular disease in the allele model](MGG3-7-e888-g002){#mgg3888-fig-0002}

3.3. Test of heterogeneity {#mgg3888-sec-0013}
--------------------------

Using the chi‐square test and fixed effects model, we observed the statistically significant heterogeneity in trials (Allele model G vs. A: *p* = .000, *I* ^2^ \> 50%; dominant model GG/AG vs. AA: *p* = .000, *I* ^2^ ＞ 50%; recessive model GG vs. AG/ AA: *p* = .000, *I* ^2^ \> 50%; homozygote comparison model GG vs. AA: *p* = .000, *I* ^2^ \> 50%; heterozygote comparison model GA vs. AA: *p* = 0.000, *I* ^2^ \> 50%) (Tables [3](#mgg3888-tbl-0003){ref-type="table"} and [4](#mgg3888-tbl-0004){ref-type="table"}). Thus, the wider CIs will be generated by the random‐effect model.

3.4. Sensitivity analysis and Bias diagnostics {#mgg3888-sec-0014}
----------------------------------------------

To evaluate the stability of the pooled results, sensitivity analysis was performed. The result showed that there were no substantial changes in ORs after canceling each study (Figure [3](#mgg3888-fig-0003){ref-type="fig"}). As to the publication bias, it was estimated by the Begg\'s funnel plots and Egger\'s tests. The funnel plot shapes did not reveal obvious evidence of asymmetry (Figure [4](#mgg3888-fig-0004){ref-type="fig"}). Additionally, according to the result of Egger\'s tests, the *p* values greater than 0.05 (G vs. A: *p* = .814; GG/AG vs. AA: *p* = .789; GG vs. AG/ AA: *p* = .253; GG vs. AA: *p* = .312; GA vs. AA: *p* = .855), which providing statistical evidence to the funnel plots' symmetry.

![Sensitivity analyses of the summary odds ratio coefficients for the allele model in the overall meta‐analysis](MGG3-7-e888-g003){#mgg3888-fig-0003}

![Begg\'s funnel plot from the meta‐analysis of cardiovascular disease risk and *IL‐10*‐1082A/G polymorphism in the allele model](MGG3-7-e888-g004){#mgg3888-fig-0004}

4. DISCUSSION {#mgg3888-sec-0015}
=============

Cardiovascular disease is broadly testified as atherosclerosis, underlying vascular aberrations, as well as formation of coronary plaques (Malik et al., [2004](#mgg3888-bib-0037){ref-type="ref"}; Strazzullo, D'Elia, Kandala, & Cappuccio, [2009](#mgg3888-bib-0050){ref-type="ref"}; Vasan, [2006](#mgg3888-bib-0056){ref-type="ref"}). Many studies identified that the potential influence of inflammatory cascade in many kinds of CVD. Inflammatory responses could trigger and accelerate vascular injury and CVDs risk (Lakka et al., [2002](#mgg3888-bib-0028){ref-type="ref"}; Malik et al., [2004](#mgg3888-bib-0037){ref-type="ref"}). Therefore, the pathogenesis of CVDs have been deemed as both genetic and inflammatory pathways, which modulated by various inflammatory cytokines. Genetic factors are regarded as strong determinants of CVDs (Brigitta, [2007](#mgg3888-bib-0004){ref-type="ref"}; Mckusick, [1959](#mgg3888-bib-0040){ref-type="ref"}). According to the chromosomal location and functional relevance, *IL‐10* is a multifunctional cytokine that has been considered as a candidate gene for kinds of CVD (Couper, Blount, & Riley, [2008](#mgg3888-bib-0008){ref-type="ref"}; Dopheide et al., [2015](#mgg3888-bib-0011){ref-type="ref"}; Eskdale, Wordsworth, Bowman, Field, & Gallagher, [2010](#mgg3888-bib-0013){ref-type="ref"}; Heeschen et al., [2003a](#mgg3888-bib-0019){ref-type="ref"}). Therefore, this meta‐analysis was performed to obtain a more precise conclusion and to make a better understanding of *IL‐10* (−1082 G/A) SNP with CVDs risk.

For this meta‐analysis, we aimed to identify the dispute about the role of *IL‐10* (−1082 G/A) in CVD risk. The results showed that there exists a significant relationship between *IL‐10* (−1082 G/A) and CVDs risk. This study was conducted by critically evaluating 31 individual case--control studies involving the *IL‐10* (−1082 G/A) polymorphism and CVDs risk. We found that the *IL‐10* (−1082 G/A) was associated with an increased risk of CVDs among Asians. As far as we know, this updated meta‐analysis includes the largest samples and the most cogent conclusions.

In our study, we observed that the allele and genotype frequencies of *IL‐10* (−1082A/G) were associated with CVDs risk, which was consistent with a present study, as reported by Yang et al. (Xuan, Wang, Zhi, Li, & Wei, [2016](#mgg3888-bib-0057){ref-type="ref"}). One meta‐analysis study observed that the allele and genotype frequencies of *IL‐10* (−1082A/G) were not associated with ischemic stroke risk (Liu, Hui‐Min, et al., [2017](#mgg3888-bib-0034){ref-type="ref"}). However, the powerful relationship between *IL‐10* (−1082A/G) and ischemic stroke has been found in the Italian population (Tuttolomondo et al., [2012a](#mgg3888-bib-0055){ref-type="ref"}). Li et al. reported that *IL‐10* −1082G/A was related to increase the atherosclerotic risk (Chao, Lei, & Fei, [2014](#mgg3888-bib-0005){ref-type="ref"}). Wang et al. observed that *IL‐10* (−1082A/G) polymorphism was significantly associated with increasing the cerebral infarction risk in Asians (Fan et al., [2016](#mgg3888-bib-0014){ref-type="ref"}). Based on the Asian population, several studies have indicated the positive or null relationship of *IL‐10* (−1082A/G) with CVDs, and the results remain controversial. Although previous individual studies have reported an association, the overall result of the present analysis support the relationship between *IL‐10* −1082G/A polymorphism and CVD risk in all genetic models. There are three potential reasons can explain the difference among these findings. First, the relatively small sample sizes of included studies might lead to false positive or negative results. Second, the inconsistent results could result from different genotype frequencies among enrolled subjects, especially in different ethnic groups. Third, due to the complicated pathogenesis of CVDs, it is difficult to explain that the SNP in a single gene could increase risk of CVD without a contribution of other polymorphic susceptibility genes.

Limitations also exist in our study. First, the study lack of detailed information in patients. Second, the studies with small sample size (\<100 cases and controls) may overestimate the relationship. Third, the origins of heterogeneity may contain many factors, such as the diverse characteristics of the control group and the different methods of diverse genotyping. Finally, the human *IL‐10* production is regulated by the complicated interaction between gene and environment, the effect of single genetic mutation is limited. So the evidence offered by this meta‐analysis should be accepted with caution. However, our study also exist some advantages: the reasonable‐designed search and selection method could increase the statistical power and the accuracy of the results, at the same time, the results did not show any evidence of publication bias.

In conclusion, the results of our study indicate that the *IL‐10* −1082A/G polymorphism is associated with an increased risk of CVDs. In subsequent studies, we will conduct functional studies to confirm our conclusions.
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